which may be linked to the conjugation technology used in the drug and features as a black box warning on the product's label. The risk is said to be behind the somewhat slow take-up of Enhertu ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

AstraZeneca believes the taxes are related to cancer drug Imfinzi, but Enhertu could be implicated as well, Leerink Partners analyst Andrew Berens said. Enhertu is a breast cancer treatment.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

In the study, Enhertu was given to patients with HER2-low ... which features as a black box warning on the product's label. DESTINY-Breast03 and 04 as well as data in HER2-positive non-small ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday celebrated another approval of their cancer drug Enhertu. The Cambridge, England-based and Tokyo-based pharmaceutical ...